Table 3.
Toxicity spectra and rankings based on each specific irAEs.
| 1st | 2nd | 3rd | 4th | 5th | |
|---|---|---|---|---|---|
| Gastrointestinal irAE | |||||
| sColitis G1-5 | Dual ICIs (91.6) | ICI monotherapy + CT (54.0) | ICI monotherapy (61.8) | Chemotherapy (99.9) | – |
| Colitis G3-5 | Dual ICIs (92.3) | ICI monotherapy + CT (57.2) | ICI monotherapy (63.7) | Chemotherapy (98.8) | – |
| Diarrhea G1-5 | ICI monotherapy + CT (94.9) | Chemotherapy (68.1) | Dual ICIs (64.5) | ICI monotherapy (96.4) | – |
| Diarrhea G3-5 | ICI monotherapy + CT (81.6) | Dual ICIs (52.4) | Chemotherapy (57.9) | ICI monotherapy (82.0) | – |
| Pulmonary irAE | |||||
| Pneumonitis G1-5 | Dual ICIs (95.2) | ICI monotherapy (64.1) | Dual ICIs + CT (31.9) | ICI monotherapy + CT (58.6) | Chemotherapy (98.5) |
| Pneumonitis G3-5 | Dual ICIs (88.5) | ICI monotherapy (62.6) | Dual ICIs + CT (35.4) | ICI monotherapy + CT (67.9) | Chemotherapy (87.1) |
| Endocrine irAE | |||||
| Hyperthyroidism G1-5 | Dual ICIs (92.7) | ICI monotherapy (58.5) | Dual ICIs + CT (51.3) | ICI monotherapy + CT (89.2) | Chemotherapy (100.0) |
| Hyperthyroidism G3-5 | Dual ICIs + CT (57.1) | Dual ICIs (32.2) | ICI monotherapy + CT (29.1) | ICI monotherapy (25.4) | Chemotherapy (31.8) |
| Hypothyroidism G1-5 | Dual ICIs (88.0) | ICI monotherapy (76.6) | Dual ICIs + CT (45.3) | ICI monotherapy + CT (60.8) | Chemotherapy (100.0) |
| Hypothyroidism G3-5 | Dual ICIs + CT (83.9) | Dual ICIs (38.4) | ICI monotherapy + CT (28.2) | ICI monotherapy (36.3) | Chemotherapy (57.6) |
| Thyroiditis G1-5 | Dual ICIs (47.6) | ICI monotherapy (35.7) | ICI monotherapy + CT (32.0) | Dual ICIs + CT (30.3) | Chemotherapy (87.1) |
| Thyroiditis G3-5 | Dual ICIs + CT (34.5) | ICI monotherapy + CT (27.7) | Chemotherapy (34.4) | ICI monotherapy (32.3) | Dual ICIs (31.6) |
| Hypophysitis G1-5 | Dual ICIs + CT (58.6) | Dual ICIs (44.3) | ICI monotherapy + CT (40.5) | ICI monotherapy (47.6) | Chemotherapy (88.3) |
| Hypophysitis G3-5 | Dual ICIs (57.5) | Dual ICIs + CT (24.0) | ICI monotherapy (33.8) | ICI monotherapy + CT (38.7) | Chemotherapy (66.0) |
| Diabetes G1-5 | Dual ICIs (62.7) | ICI monotherapy + CT (43.7) | Dual ICIs + CT (24.0) | ICI monotherapy (27.4) | Chemotherapy (39.0) |
| Diabetes G3-5 | Dual ICIs (49.3) | ICI monotherapy + CT (39.5) | Dual ICIs + CT (22.4) | ICI monotherapy (27.0) | Chemotherapy (38.3) |
| Skin irAE | |||||
| Pruritus G1-5 | ICI monotherapy + CT (42.4) | Dual ICIs (23.9) | ICI monotherapy (38.8) | Chemotherapy (87.0) | – |
| Pruritus G3-5 | ICI monotherapy + CT (57.6) | Dual ICIs (22.1) | Chemotherapy (38.0) | ICI monotherapy (46.2) | – |
| Rash G1-5 | Dual ICIs + CT (51.8) | Dual ICIs (49.0) | ICI monotherapy + CT (62.5) | ICI monotherapy (64.6) | Chemotherapy (99.3) |
| Rash G3-5 | Dual ICIs + CT (89.6) | ICI monotherapy + CT (49.5) | Dual ICIs (25.1) | ICI monotherapy (36.8) | Chemotherapy (70.0) |
| Severe skin reaction G1-5 | Dual ICIs (88.4) | ICI monotherapy (86.2) | ICI monotherapy + CT (87.2) | Chemotherapy (91.1) | – |
| Severe skin reaction G3-5 | Dual ICIs (93.4) | ICI monotherapy (87.0) | ICI monotherapy + CT (79.3) | Chemotherapy (87.5) | – |
| Other irAE | |||||
| Myocarditis G1-5 | Dual ICIs (61.1) | ICI monotherapy (44.6) | Dual ICIs + CT (30.2) | Chemotherapy (40.2) | ICI monotherapy + CT (49.7) |
| Myocarditis G3-5 | Dual ICIs (60.0) | ICI monotherapy (42.2) | Dual ICIs + CT (28.8) | Chemotherapy (37.7) | ICI monotherapy + CT (37.4) |
| Nephritis G1-5 | ICI monotherapy + CT (42.4) | Dual ICIs (23.9) | ICI monotherapy (38.8) | Chemotherapy (87.0) | – |
| Nephritis G3-5 | ICI monotherapy + CT (57.6) | Dual ICIs (22.1) | Chemotherapy (38.0) | ICI monotherapy (46.2) | – |
| Hepatitis G1-5 | Dual ICIs (75.6) | ICI monotherapy (44.7) | Dual ICIs + CT (38.1) | ICI monotherapy + CT (69.6) | Chemotherapy (98.5) |
| Hepatitis G3-5 | Dual ICIs + CT (49.8) | Dual ICIs (25.8) | ICI monotherapy + CT (38.2) | ICI monotherapy (60.0) | Chemotherapy (93.6) |
| Myositis G1-5 | Dual ICIs (52.8) | ICI monotherapy (48.7) | ICI monotherapy + CT (34.7) | Chemotherapy (53.4) | – |
| Myositis G3-5 | Dual ICIs (55.2) | ICI monotherapy + CT (25.0) | Chemotherapy (35.7) | ICI monotherapy (44.4) | – |
| Hypersensitivity/infusion reaction G1-5 | Dual ICIs + CT (77.3) | Dual ICIs (39.6) | ICI monotherapy + CT (25.3) | ICI monotherapy (34.0) | Chemotherapy (45.1) |
| Hypersensitivity/infusion reaction G3-5 | ICI monotherapy + CT (64.7) | Chemotherapy (33.8) | Dual ICIs + CT (16.7) | Dual ICIs (27.3) | ICI monotherapy (36.5) |
The value in each parenthesis represents the probability of risk to rank (%). ICI, immune checkpoint inhibitor; CT, chemotherapy; irAE, immune-related adverse event; G, grade.